AC
DSGN icon

Almitas Capital’s Design Therapeutics DSGN Stock Holding History

Almitas Capital’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Sell
1,026,893
-503,442
-33% -$6.28M 3.56% 5
2026
Q1 		$16.3M Sell
1,530,335
-100
-0% -$1.01K 3.68% 5
2025
Q4 		$14.4M Hold
1,530,435
– – 3.16% 8
2025
Q3 		$11.5M Hold
1,530,435
– – 2.64% 6
2025
Q2 		$5.16M Buy
1,530,435
+77,539
+5% +$290K 1.3% 15
2025
Q1 		$5.61M Buy
1,452,896
+129,229
+10% +$617K 1.86% 7
2024
Q4 		$8.17M Hold
1,323,667
– – 1.79% 10
2024
Q3 		$7.12M Buy
1,323,667
+70,419
+6% +$331K 2.52% 10
2024
Q2 		$4.2M Buy
1,253,248
+227,180
+22% +$885K 1.75% 15
2024
Q1 		$4.14M Hold
1,026,068
– – 1.71% 19
2023
Q4 		$2.72M Buy
+1,026,068
New +$2.35M 0.94% 32

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Almitas Capital's DSGN Position: Q2 2026 in Review

Almitas Capital reduced its Design Therapeutics (DSGN) stake by 33% in Q2 2026, selling an estimated $6.28M and leaving 1,026,893 shares worth $14.9M. The position accounts for 3.56% of the portfolio, ranked #5.

Almitas Capital first reported a position in DSGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $16.3M in Q1 2026. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Almitas Capital held 1,026,893 shares of Design Therapeutics worth $14.9M as of Q2 2026.
  • Almitas Capital sold 503,442 Design Therapeutics shares in Q2 2026, an estimated $6.28M.
  • Design Therapeutics made up 3.56% of Almitas Capital's portfolio in Q2 2026, its #5 holding.
  • Almitas Capital first reported a position in Design Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Almitas Capital's Design Therapeutics position peaked at $16.3M in Q1 2026.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Almitas Capital's 13F filing for Q2 2026, filed 17 Aug 2026.